New antibiotic class showing no resistance development
GmPcides are a new class of antibiotics effective against multidrug resistant gram-positive bacteria such as Staphylococcus aureus, Streptococcus pyogenes and Enterococcus ssp, including drug-resistant strains such as MRSA and VRE. GmPcides belong to a new chemical class, have new target and a new mode of action and there is no cross-resistance to other antibiotic class, i.e. they fulfil all four WHO innovativeness criteria.
QureTech Bio’s lead program is focusing on developing a new monotherapy for treatment of serious infections caused by Gram-positive bacteria. The program is supported by ENABLE-2 (financed by Vinnova) and is currently in lead optimization phase.